14.15

0.07% -0.015

Enanta Pharmaceuticals Inc (ENTA)

Overview News Price History Option Chain Financials Discussions Forecast

Enanta Pharmaceuticals Inc stock is traded at $14.15, with a volume of 48,163. It is down -0.07% in the last 24 hours and up +29.67% over the past month. Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Previous Close:

$14.17

Open:

$14.07

24h Volume:

48,163

Relative Volume:

0.07

Market Cap:

$408.41M

Revenue:

$66.59M

Net Income/Loss:

$-104.93M

P/E Ratio:

-2.8596

EPS:

-4.95

Net Cash Flow:

$-96.48M

1W Performance:

+0.28%

1M Performance:

+29.67%

6M Performance:

+96.39%

1Y Performance:

+76.78%

1-Day Range:

$13.89

$14.25

1-Week Range:

$13.80

$14.52

52-Week Range:

$4.09

$15.34

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name

Enanta Pharmaceuticals Inc

Sector

Healthcare (1136)

Industry

Biotechnology (632)

Phone

617 607 0800

Address

4 KINGSBURY AVENUE, WATERTOWN, MA

Employee

120

Twitter

@EnantaPharma

Next Earnings Date

2025-02-10

Latest SEC Filings

ENTA's Discussions on Twitter

Compare ENTA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ENTA Enanta Pharmaceuticals Inc	14.15	406.67M	66.59M	-104.93M	-96.48M	-4.95
VRTX Vertex Pharmaceuticals Inc	456.61	116.04B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	718.66	75.97B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	455.88	61.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	894.37	56.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	203.40	43.73B	447.02M	-1.18B	-906.14M	-6.1812

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-14-25	Initiated	JP Morgan	Overweight
Oct-01-25	Upgrade	Jefferies	Hold → Buy
Jul-28-25	Resumed	H.C. Wainwright	Buy
Aug-09-23	Downgrade	JP Morgan	Neutral → Underweight
Aug-08-23	Downgrade	Jefferies	Buy → Hold
Dec-09-22	Initiated	H.C. Wainwright	Buy
Jul-06-22	Upgrade	Evercore ISI	In-line → Outperform
Jun-01-22	Upgrade	Evercore ISI	Underperform → In-line
Oct-07-21	Initiated	Jefferies	Buy
Sep-09-21	Initiated	SVB Leerink	Mkt Perform
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral
Nov-24-20	Initiated	Evercore ISI	Underperform
Aug-28-20	Resumed	ROTH Capital	Buy
Aug-26-20	Initiated	Piper Sandler	Overweight
Jul-27-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Mar-17-20	Upgrade	Robert W. Baird	Neutral → Outperform
Nov-22-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-26-19	Downgrade	JP Morgan	Neutral → Underweight
May-24-19	Initiated	Wolfe Research	Outperform
Apr-23-19	Upgrade	Berenberg	Hold → Buy
Dec-13-18	Initiated	Berenberg	Hold
Jun-06-18	Initiated	ROTH Capital	Buy
Feb-08-18	Downgrade	JP Morgan	Overweight → Neutral
Jan-02-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-21-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Jul-11-17	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Apr-28-16	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-09-16	Reiterated	Barclays	Underweight
Oct-23-15	Downgrade	Barclays	Equal Weight → Underweight
Oct-23-15	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform

View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

06:00 AM

Will Enanta Pharmaceuticals Inc. (9EP) stock extend growth storyJuly 2025 Intraday Action & Daily Profit Focused Screening - Newser

06:00 AM

Dec 04, 2025

Can Enanta Pharmaceuticals Inc. (9EP) stock survive global slowdownJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - Newser

Dec 04, 2025

Is Enanta Pharmaceuticals Inc. (9EP) stock nearing a technical breakout - Newser

Dec 04, 2025

Is Enanta Pharmaceuticals Inc. stock a top momentum playQuarterly Market Summary & Risk Controlled Daily Trade Plans - Newser

Dec 04, 2025

Dec 03, 2025

VP Or Surrenders 753 Of Enanta Pharmaceuticals Inc [ENTA] - TradingView

Dec 03, 2025

ENTA: RSV and immunology pipelines advance with key candidates and pivotal trials planned for 2026 - TradingView

Dec 03, 2025

Dec 02, 2025

Is Enanta Pharmaceuticals Inc. (9EP) stock a defensive play amid uncertainty - Newser

Dec 02, 2025

Nov 30, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 30, 2025

Nov 29, 2025

Certain Options of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener

Nov 29, 2025

Certain Common Stock of Enanta Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - marketscreener.com

Nov 29, 2025

Does Enanta Pharmaceuticals Inc. stock trade at a discount to peersTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ

Nov 29, 2025

Portfolio Recap: What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds2025 Winners & Losers & Risk Adjusted Swing Trade Ideas - BỘ NỘI VỤ

Nov 29, 2025

Enanta Pharmaceuticals Inc Stock Analysis and ForecastMarket Capitalization Trends & Free Unmatched Market Performance - earlytimes.in

Nov 29, 2025

Nov 27, 2025